{"id":"https://openalex.org/W2201134166","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.3570","title":"AMG 102, an HGF/SF antagonist, in combination with anti-angiogenesis targeted therapies in adult patients with advanced solid tumors","display_name":"AMG 102, an HGF/SF antagonist, in combination with anti-angiogenesis targeted therapies in adult patients with advanced solid tumors","publication_year":2008,"publication_date":"2008-05-20","ids":{"openalex":"https://openalex.org/W2201134166","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.3570","mag":"2201134166"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2008.26.15_suppl.3570","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.3570","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.3570","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111763210","display_name":"Peter J. Rosen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. J. Rosen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002909668","display_name":"Christopher J. Sweeney","orcid":"https://orcid.org/0000-0002-0398-6018","observed_orcids":["https://orcid.org/0000-0002-0398-6018"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. J. Sweeney","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015721543","display_name":"D. J. Park","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. J. Park","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001183616","display_name":"Erik Rasmussen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. Rasmussen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061549439","display_name":"Poornima Shubhakar","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. Shubhakar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069214839","display_name":"Charity D. Scripture","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Scripture","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013191523","display_name":"Ian M. Leitch","orcid":"https://orcid.org/0000-0002-2465-3036","observed_orcids":["https://orcid.org/0000-0002-2465-3036"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"I. Leitch","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105141446","display_name":"Juan L\u00fc","orcid":"https://orcid.org/0000-0002-9139-0678","observed_orcids":["https://orcid.org/0000-0002-9139-0678"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Lu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002011167","display_name":"Darrin M. Beaupre","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. M. Beaupre","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5088473266","display_name":"Lorrin Yee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. K. Yee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":16,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":"15_suppl","first_page":"3570","last_page":"3570"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.8695999979972839,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.8695999979972839,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.05620000138878822,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10073","display_name":"Hepatocellular Carcinoma Treatment and Prognosis","score":0.03500000014901161,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/c-met","display_name":"c-Met","score":0.8640000224113464},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9589999914169312},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.8809999823570251},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8090000152587891},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8029999732971191},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7609999775886536},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8240000009536743},{"id":"https://openalex.org/keywords/carcinoid-tumor","display_name":"carcinoid tumor","score":0.7889999747276306},{"id":"https://openalex.org/keywords/endometrial-cancer","display_name":"endometrial cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/vegf-signaling-pathway","display_name":"VEGF pathway","score":0.6809999942779541},{"id":"https://openalex.org/keywords/synergistic-antitumor-effect","display_name":"synergistic antitumor effect","score":0.7229999899864197}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8726105690002441},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7642631530761719},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.6797795295715332},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5834008455276489},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.5682218670845032},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.5196570158004761},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48846545815467834},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4865683317184448},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4762715995311737},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.41330602765083313},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.37766239047050476},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.3716384768486023}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2008.26.15_suppl.3570","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.3570","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.3570","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9922999739646912}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2163981356","https://openalex.org/W3010187320","https://openalex.org/W2167344440","https://openalex.org/W2153933602","https://openalex.org/W1979479955","https://openalex.org/W2802922348","https://openalex.org/W2161880708","https://openalex.org/W2280309969","https://openalex.org/W3127636830","https://openalex.org/W2150648786"],"abstract_inverted_index":{"3570":[0],"Background:":[1],"AMG":[2,54,84,102,201,287,316],"102":[3,85,103,202,249,266,288,317],"is":[4],"a":[5,221,243,260],"novel,":[6],"fully":[7],"human":[8],"monoclonal":[9],"antibody":[10],"that":[11],"selectively":[12],"targets":[13],"hepatocyte":[14],"growth":[15],"factor/scatter":[16],"factor":[17],"(HGF/SF),":[18],"the":[19,23,36,48,215,278],"only":[20],"ligand":[21],"for":[22,238,309],"c-Met":[24],"receptor,":[25],"potentially":[26],"inhibiting":[27],"tumor":[28,44,120,218,247,307],"cell":[29],"proliferation,":[30],"survival,":[31],"and":[32,35,119,146,172,184,220,255,304],"invasion.":[33],"Bevacizumab":[34],"small-molecule":[37],"tyrosine":[38],"kinase":[39],"inhibitor":[40],"motesanib":[41,111,253],"diphosphate":[42,112],"deter":[43],"angiogenesis":[45],"by":[46,62],"disrupting":[47],"VEGF":[49],"pathway;":[50],"in":[51,130,203,214,229,242,259,275,289],"combination":[52,204,290],"with":[53,79,133,205,245,262,291,299],"102,":[55],"they":[56],"may":[57,305],"have":[58],"synergistic":[59],"antitumor":[60],"effects":[61],"targeting":[63],"multiple":[64],"signaling":[65],"pathways.":[66],"Methods:":[67],"In":[68],"an":[69,300],"open-label":[70],"Phase":[71,312],"1b":[72],"study,":[73],"3":[74,104,148,250],"cohorts":[75],"of":[76,150,191,200,217,224,231,271,280,315],"3\u20136":[77],"patients":[78,100,135,163],"advanced":[80],"solid":[81],"tumors":[82],"received":[83,101],"(3,":[86],"10,":[87],"or":[88,326,329],"20":[89],"mg/kg)":[90],"+":[91,108,252],"bevacizumab":[92],"10":[93,232,267],"mg/kg":[94,105,251,268,320],"every":[95],"2":[96,99,313],"weeks":[97],"(Q2W);":[98],"IV":[106],"Q2W":[107],"daily":[109],"oral":[110],"75":[113],"mg.":[114],"Safety,":[115],"tolerability,":[116],"pharmacokinetics":[117],"(PK),":[118],"response":[121,223],"(RECIST)":[122],"were":[123,156,227],"assessed.":[124],"Results:":[125],"Patient":[126],"enrollment":[127],"was":[128,193,208],"complete":[129],"April":[131],"2007":[132],"14":[134],"(7":[136],"men,":[137],"mean":[138],"age":[139],"67).":[140],"Prior":[141],"treatment":[142],"included":[143,177],"radiotherapy":[144],"(50%)":[145],"\u2265":[147],"lines":[149],"chemotherapy":[151],"(71%).":[152],"No":[153],"dose-limiting":[154],"toxicities":[155],"seen":[157,228],"at":[158,318],"any":[159],"dosing":[160],"levels.":[161],"All":[162],"reported":[164],"treatment-related":[165,175],"adverse":[166],"events":[167],"(AEs),":[168],"most":[169],"commonly":[170],"nausea":[171],"fatigue.":[173],"Serious":[174],"AEs":[176],"pulmonary":[178],"embolism":[179],"(PE)":[180],"(n":[181,186],"=":[182,187],"1)":[183],"hypotension":[185],"1).":[188],"Another":[189],"case":[190],"PE":[192],"deemed":[194],"not":[195],"treatment-related.":[196],"The":[197],"PK":[198],"profile":[199],"anti-angiogenic":[206],"agents":[207,293],"similar":[209],"to":[210,283,295],"monotherapy.":[211],"A":[212],"decrease":[213],"sum":[216],"diameters":[219],"best":[222],"stable":[225],"disease":[226,236],"8":[230],"evaluable":[233],"patients.":[234,311],"Stable":[235],"persisted":[237],">":[239,256],"12":[240],"months":[241,258],"patient":[244,261],"carcinoid":[246],"(AMG":[248,265],"diphosphate)":[254],"9":[257],"endometrial":[263],"cancer":[264],"+bevacizumab).":[269],"Levels":[270],"plasma":[272],"HGF":[273],"increased":[274],"all":[276],"patients;":[277],"magnitude":[279],"increase":[281],"appeared":[282,294],"be":[284,296],"dose-dependent.":[285],"Conclusions:":[286],"anti-angiogenesis":[292],"well":[297],"tolerated":[298],"acceptable":[301],"safety":[302],"profile,":[303],"inhibit":[306],"progression":[308],"some":[310],"evaluations":[314],"10\u201320":[319],"are":[321],"underway.":[322],"Author":[323],"Disclosure":[324],"Employment":[325],"Leadership":[327],"Consultant":[328],"Advisory":[330],"Role":[331],"Stock":[332],"Ownership":[333],"Honoraria":[334],"Research":[335],"Expert":[336],"Testimony":[337],"Other":[338],"Remuneration":[339],"Amgen":[340,342,344,346],"Inc.":[341,343,345,347]},"counts_by_year":[{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}